Pace Life Sciences Lands Role in Centillion-Led ARPA-H GIVE Award for RNA Medicine Manufacturing
Pace Life Sciences joins Centillion-led ARPA-H GIVE award to advance RNA medicine manufacturing with integrated, point-of-care personalized production.
Research Desk
Traditional pharmaceutical manufacturing is organized around scale: production runs of thousands of doses or more, a model that Pace Life Sciences describes as labor-intensive, costly, and poorly suited to personalized medicine.
A Platform Built for One Patient at a Time
On November 12, 2026, the company announced it has joined a consortium led by Centillion Biosciences, Inc. that was selected by the Advanced Research Projects Agency for Health (ARPA-H) under its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, an initiative aimed at lowering the cost of medications for people with rare and ultra-rare genetic diseases and improving access to them.
The consortium's answer to that problem is a compact, integrated manufacturing system built on Centillion's GMP-qualified Biofoundary-in-a-Box™ (BiaB™) platform and its patented continuous-flow technologies. The system is designed to carry a therapy from DNA input through RNA production to fill-finish, with quality testing built directly into the process rather than handled as a separate step.
Distributed Production Near the Point of Care
Beyond the integrated workflow, the platform is intended to support a distributed manufacturing model, with systems deployed closer to the patients who need these medicines.
The GIVE program's long-term vision is a manufacturing network capable of producing individualized RNA-based medicines at or near the point of care, with automated systems and integrated quality control designed around small patient populations.
For diseases so rare that a therapy may only ever be needed by a handful of individuals, the company stated that these innovations could determine whether a treatment remains theoretical or actually reaches patients.
What Pace Brings to the Project
Pace® Life Sciences, a division of Pace®, a science and technology company, is contributing to the design and development of the integrated manufacturing platform through the build and proof-of-concept testing stages. Its involvement is expected to continue into later phases, when the platform is slated for installation at Pace® Life Sciences laboratories to support production.
The company pointed to real-world drug products developed for Dana-Farber Cancer Institute, Boston Children's Hospital, Miltenyi Biotec, HDT Bio, and Violet Pharmaceuticals as evidence of its range across different RNA molecules, lipid nanoparticle formulations, and disease applications. Peter Abbink, Ph.D., Boston Site Head at Pace® Life Sciences, said the current drug manufacturing process creates long timelines and high costs for personalized medicines.
"Putting manufacturing and quality into one integrated system that can produce a clinical drug product for a very small patient population becomes something we can realistically do, not just imagine," he said.
Andy Fenny, President of Pace® Life Sciences, said the company is proud to join the initiative alongside organizations advancing individualized genetic medicines. "For these therapies to become more accessible, manufacturing must evolve beyond traditional large-scale models. Pace® brings the scientific, manufacturing and quality expertise to help translate that vision into a practical platform designed for smaller patient populations," he said.
How the Consortium Came Together
Pace's participation began before the award announcement, through an ARPA-H partnering event convened to connect industry and academic organizations around the technical and manufacturing challenges of individualized genetic medicines.
The Centillion-led consortium that emerged spans genetic medicine development, engineering, manufacturing, analytical science, automation, and quality. In addition to Pace® Life Sciences, participants include Dana-Farber Cancer Institute, Harvard Medical School, Boston Children's Hospital, Triple Ring Technologies, Legomics, Molariti, HDT Bio, p-Chip, and other specialist collaborators.
Abbink and Centillion founder Harris Makatsoris recently appeared on The Biotech Voyager, hosted by Benjamin McLeod, where they discussed the program and the future of RNA manufacturing, according to the announcement.
About Pace Life Sciences
Pace® Life Sciences serves pharmaceutical and biopharmaceutical clients developing therapies, with services that range from early R&D and clinical trial materials production to analytical testing and commercial-stage support.
Through its network of U.S.-based facilities, the company provides regulatory, quality, and laboratory operations support. Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.
Tracked in the database
Personalized RNA Medicine Manufacturing / Distributed Biomanufacturing · North America
Personalized RNA Medicine Manufacturing / Distributed Biomanufacturing
North America
Market Research
13 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.